USPs that matters:

$kyrocking Ca$hcows

AI triggered Signals

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Turnkey solutions: ayondo Franchise

& more ...

Tipp: Hedge Fund Activity Tracker ("HFAT")

Info-Hub

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Campus

Education
Webinars
Mentoring

Press

FAQ

What's New

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Home
Terminal
Spexis AG

Spexis AG

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

H63556106

SEDOL

N/A

CIK

N/A

spexisbio.com

LEI: 391200S8HJE1I96FIG04

New: Infographics X-Lab

FIGI: BBG000R25GY7

SPEX

Spexis AG

GICS: - · Sector: - · Sub-Sector: -

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Spexis Bio

Click to initiate

ENTERPRISE

NAME

Spexis AG

ISIN

CH0106213793

TICKER

SPEX

MIC

XSWX

REUTERS

SPEX.S

BLOOMBERG

SPEX SW

F&G: 62

12.093,00 SMI · 21,93 Vola-Index · 103.207,61 BTC · 0,93542 EURCHF

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Tue, 05.11.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 4 November 2024 Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it expects the Swiss SIX exch...

Research & Analysis

Mon, 29.07.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 29 July 2024 Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focuse...

Research & Analysis

Mon, 22.07.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 22 July 2024 Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on m...

Research & Analysis

Mon, 08.07.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 8 July, 2024 PARI Pharma GmbH announces termination of ColiFin® license to EnBiotix, Inc. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that PARI Pharma GmbH (“PARI”), the owne...

Research & Analysis

Tue, 04.06.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 4, 2024 Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that the company...

Research & Analysis

Tue, 04.06.2024

Research & Analysis

Fri, 31.05.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 31, 2024 Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company...

Research & Analysis

Tue, 30.04.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 30, 2024 Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024. Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for ra...

Research & Analysis

Tue, 30.04.2024

Research & Analysis

Wed, 17.04.2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 17, 2024 Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera The Western District Court of the Canton Basel-Landschaft has granted Spexis...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 24.350 Visitors - 21.622 Registered members - 14 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Made in Germany

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Visual Sitemap

Helpdesk

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Consumer information

Imprint

smart.AD